Compare BIO-TECHNE Corp (TECH) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Visa Inc — how do they compare? BIO-TECHNE Corp trades at $72.06 (market cap $11.24B), while Visa Inc trades at $363.57 (market cap $668.96B). The key difference: Visa Inc is far larger — about 59.5× BIO-TECHNE Corp's market cap, and Visa Inc pays the higher dividend (0.74%). Which is the better fit depends on your goals.
| TECH | V | |
|---|---|---|
Market Cap | $11.24B | $668.96B |
Sector | Health | Financials |
52-Week High | $72.29 | $370.47 |
52-Week Low | $43.31 | $295.52 |
Enterprise Value | $11.32B | $679.54B |
Dividend Yield | 0.44% | 0.74% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Visa (V) trades at $363.81, up 0.36% on the day, with strong fundamentals including a 50.78% net income margin and consistent earnings beats. The stock shows a bearish technical signal but benefits from bullish analyst sentiment, with an 85% buy rating and a $426.31 consensus price target. Recent news highlights AI-driven initiatives like Intelligent Commerce Connect to enhance payment efficiency.
Outlook remains positive due to robust profitability and growth in digital payments, though risks include fintech competition and regulatory pressures. The stock offers a solid dividend yield and institutional confidence, positioning it for long-term value if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
